2012
DOI: 10.7326/0003-4819-157-12-201212180-00004
|View full text |Cite
|
Sign up to set email alerts
|

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Abstract: Abbott Laboratories.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

13
352
1
22

Year Published

2013
2013
2017
2017

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 375 publications
(388 citation statements)
references
References 26 publications
13
352
1
22
Order By: Relevance
“…Adams et al showed no difference in outcome from the placebo group [22]. Another study on etanercept showed 30% no change, 30% long term disease improvement and effectiveness, and a 30% requiring additional dosing after 1 year for recurrence of disease; a similar efficacy rate was also observed by Lee et al at 20% [23,24].…”
Section: Immunomodulatorssupporting
confidence: 57%
“…Adams et al showed no difference in outcome from the placebo group [22]. Another study on etanercept showed 30% no change, 30% long term disease improvement and effectiveness, and a 30% requiring additional dosing after 1 year for recurrence of disease; a similar efficacy rate was also observed by Lee et al at 20% [23,24].…”
Section: Immunomodulatorssupporting
confidence: 57%
“…These include genetic predisposition, hormonal dysregulation and an aberrant immune response to commensal bacteria 7, 8, 9, 10. A number of exogenous influences have also been implicated in population‐based studies of HS, particularly smoking and obesity,11 although a causative relationship has not been established.…”
Section: Introductionmentioning
confidence: 99%
“…Relapszus ezen betegnél 6 esetben hat hónapon belül, míg 8 esetben több mint egy év eltelté-vel jelentkezett. Isotretinoinnal kapcsolatosan ezen szisztematikus összefoglalóban hét vizsgálat szerepel, melyek során összesen 174 beteget kezeltek 0,5-1,2 mg/kg/nap dózisban 4-12 hónapig (38) (39)(40)(41)(42). A rendelkezésre álló evidenciák alapján az adalimumab és az infliximab hatásos kezelések a betegségben, javítják a betegek életminőségét.…”
Section: áBraunclassified